FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892918973> ?p ?o ?g. }

• W2892918973 endingPage "48" @default.
• W2892918973 startingPage "37" @default.
• W2892918973 abstract "There is an unmet clinical need for early, accurate imaging of recurrent prostate cancer to improve patient outcomes. Staging, by conventional bone scintigraphy and CT have become outdated. 68Ga-PSMA PET/CT imaging in this setting has developed rapidly, with widespread International adoption in line with evidence-based guidelines in this group of patients. A PubMed search of English language articles was performed using following keywords: PSMA, PET/CT, biochemical recurrence, prostate cancer. The search revealed 85 articles, of which 75 were original; 70 of these involved use of the most widely available type of PSMA tracer (HBED). The review also relied on the clinical experience of reporting over 1000 PSMA PET/CT studies at a major tertiary referral centre for uro-oncology, with the majority of cases having been performed in the biochemical recurrence setting from 2015 to 2018. 68Ga-PSMA PET is a game changer and superior to choline PET and other established tracers which have been used in prostate cancer evaluation. Detection of recurrence at the prostate bed remains challenging due to bladder and urethral tracer accumulation. The main strength of PSMA PET/CT is its ability to identify small (<8 mm) pathological lymph nodes, upstaging nodal status in up to two-thirds of cases. Additionally, PSMA PET/CT, detects bone and bone marrow metastases missed by conventional bone and CT imaging. Thus, PSMA PET/CT has major impact on patient management, with studies reporting overall changes in 39–76% of cases. Controversy exists regarding patient access and NHS affordability of PSMA PET/CT imaging. Currently, no reimbursement is available under the NHS tariff system. The cost outlay for tertiary hospital linked PET centres ranges from £150-170 K. Large referral volumes, and technical advances in manufacturing process will make this tracer cost neutral and similar to the current funded, but less sensitive, choline PET. Current NICE guidelines for prostate cancer management do not include a recommendation on when PSMA PET/CT should be used and this is likely to remain the case in the next revision, due in 2019. Although PSMA PET/CT imaging results in significant management change, there is a need for high quality economic evaluation and cost analysis for this modality. Lack of this data will result in poor adoption of this technique and thus limit patient access. Furthermore, it is hoped that future tracers will become even more sensitive and identify disease at earlier thresholds. Well-designed clinical trials with consideration of the health economic benefit of using PSMA PET/CT will be essential to provide a basis for entry into guidelines such as NICE and to provide a rationale for reimbursement." @default.
• W2892918973 created "2018-10-05" @default.
• W2892918973 creator A5006473672 @default.
• W2892918973 creator A5008299180 @default.
• W2892918973 date "2018-09-29" @default.
• W2892918973 modified "2023-09-26" @default.
• W2892918973 title "Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer" @default.
• W2892918973 cites W1523804735 @default.
• W2892918973 cites W1541574466 @default.
• W2892918973 cites W1903999661 @default.
• W2892918973 cites W2011773693 @default.
• W2892918973 cites W2054976917 @default.
• W2892918973 cites W2077120379 @default.
• W2892918973 cites W2080006760 @default.
• W2892918973 cites W2128021809 @default.
• W2892918973 cites W2137670219 @default.
• W2892918973 cites W2184446223 @default.
• W2892918973 cites W2200412453 @default.
• W2892918973 cites W2211198407 @default.
• W2892918973 cites W2230123280 @default.
• W2892918973 cites W2287868019 @default.
• W2892918973 cites W2291594960 @default.
• W2892918973 cites W2299477037 @default.
• W2892918973 cites W2335618789 @default.
• W2892918973 cites W2340440279 @default.
• W2892918973 cites W2341951008 @default.
• W2892918973 cites W2410530509 @default.
• W2892918973 cites W2410896679 @default.
• W2892918973 cites W2412413888 @default.
• W2892918973 cites W2416073795 @default.
• W2892918973 cites W2461758752 @default.
• W2892918973 cites W2504111721 @default.
• W2892918973 cites W2540348172 @default.
• W2892918973 cites W2547821596 @default.
• W2892918973 cites W2553708763 @default.
• W2892918973 cites W2559071001 @default.
• W2892918973 cites W2561039633 @default.
• W2892918973 cites W2562588788 @default.
• W2892918973 cites W2567705791 @default.
• W2892918973 cites W2588873924 @default.
• W2892918973 cites W2589047624 @default.
• W2892918973 cites W2591849683 @default.
• W2892918973 cites W2598457068 @default.
• W2892918973 cites W2611934175 @default.
• W2892918973 cites W2612014481 @default.
• W2892918973 cites W2620052301 @default.
• W2892918973 cites W2623906261 @default.
• W2892918973 cites W2625842971 @default.
• W2892918973 cites W2673309218 @default.
• W2892918973 cites W2735797625 @default.
• W2892918973 cites W2736737591 @default.
• W2892918973 cites W2737584987 @default.
• W2892918973 cites W2766371188 @default.
• W2892918973 cites W2767882393 @default.
• W2892918973 cites W2774325924 @default.
• W2892918973 cites W2785049735 @default.
• W2892918973 cites W2785084154 @default.
• W2892918973 cites W2787120891 @default.
• W2892918973 cites W2788389042 @default.
• W2892918973 cites W2790489755 @default.
• W2892918973 cites W2790611423 @default.
• W2892918973 cites W2799931007 @default.
• W2892918973 cites W2801867624 @default.
• W2892918973 cites W286096609 @default.
• W2892918973 cites W930778287 @default.
• W2892918973 doi "https://doi.org/10.1093/bmb/ldy032" @default.
• W2892918973 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30272121" @default.
• W2892918973 hasPublicationYear "2018" @default.
• W2892918973 type Work @default.
• W2892918973 sameAs 2892918973 @default.
• W2892918973 citedByCount "4" @default.
• W2892918973 countsByYear W28929189732019 @default.
• W2892918973 countsByYear W28929189732020 @default.
• W2892918973 countsByYear W28929189732021 @default.
• W2892918973 crossrefType "journal-article" @default.
• W2892918973 hasAuthorship W2892918973A5006473672 @default.
• W2892918973 hasAuthorship W2892918973A5008299180 @default.
• W2892918973 hasBestOaLocation W28929189731 @default.
• W2892918973 hasConcept C121608353 @default.
• W2892918973 hasConcept C126322002 @default.
• W2892918973 hasConcept C126838900 @default.
• W2892918973 hasConcept C20417620 @default.
• W2892918973 hasConcept C2775842073 @default.
• W2892918973 hasConcept C2776049877 @default.
• W2892918973 hasConcept C2776235491 @default.
• W2892918973 hasConcept C2777008409 @default.
• W2892918973 hasConcept C2779466945 @default.
• W2892918973 hasConcept C2780192828 @default.
• W2892918973 hasConcept C2781114028 @default.
• W2892918973 hasConcept C2989005 @default.
• W2892918973 hasConcept C71924100 @default.
• W2892918973 hasConceptScore W2892918973C121608353 @default.
• W2892918973 hasConceptScore W2892918973C126322002 @default.
• W2892918973 hasConceptScore W2892918973C126838900 @default.
• W2892918973 hasConceptScore W2892918973C20417620 @default.
• W2892918973 hasConceptScore W2892918973C2775842073 @default.
• W2892918973 hasConceptScore W2892918973C2776049877 @default.
• W2892918973 hasConceptScore W2892918973C2776235491 @default.

• next